Andrés J Muñoz Martín1,2, Magdalena Carmen Ruiz Zamorano3, María Carmen Viñuela Benéitez3, Laura Ortega Morán4,5, Ángela García Pérez6, Miguel Martín Jiménez4,5. 1. Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España. andresmunmar@hotmail.com. 2. Cancer and Thrombosis Section, Spanish Society of Medical Oncology (SEOM), Madrid, Spain. andresmunmar@hotmail.com. 3. Department of Medicine, Faculty of Medicine, Universidad Complutense, Madrid, Spain. 4. Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España. 5. Cancer and Thrombosis Section, Spanish Society of Medical Oncology (SEOM), Madrid, Spain. 6. Radiology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
Abstract
PURPOSE: Incidentally discovered pulmonary embolism is a prevalent clinical problem for cancer patients and contributes significantly to the burden of cancer-associated thrombosis. The aim of this study was to explore if outpatient management of incidental pulmonary embolism (iPE) in cancer patients is effective and can be conducted safely. METHODS/PATIENTS: We performed a prospective observational cohort study in a single Spanish tertiary hospital. Patients diagnosed with iPE and active cancer were enrolled. Between May 2016 and May 2017, 25 consecutive patients were included in the study. RESULTS: All patients were assessed in the emergency room (ER) and started treatment with low-molecular weight heparins (LMWH) being discharged in the following 24 h. Congestive heart failure and right ventricular dysfunction were ruled out, and none of them presented massive PE, active bleeding or any disease-related reason that required hospitalization. The 90-day follow-up visit showed no venous thromboembolism (VTE) recurrence and the major bleeding rate was 4%. Mortality rate at 30 and 90 days was 0%. CONCLUSIONS: Outpatient management for iPE in cancer patients appears to be feasible and safe in selected cancer patients.
PURPOSE: Incidentally discovered pulmonary embolism is a prevalent clinical problem for cancerpatients and contributes significantly to the burden of cancer-associated thrombosis. The aim of this study was to explore if outpatient management of incidental pulmonary embolism (iPE) in cancerpatients is effective and can be conducted safely. METHODS/PATIENTS: We performed a prospective observational cohort study in a single Spanish tertiary hospital. Patients diagnosed with iPE and active cancer were enrolled. Between May 2016 and May 2017, 25 consecutive patients were included in the study. RESULTS: All patients were assessed in the emergency room (ER) and started treatment with low-molecular weight heparins (LMWH) being discharged in the following 24 h. Congestive heart failure and right ventricular dysfunction were ruled out, and none of them presented massive PE, active bleeding or any disease-related reason that required hospitalization. The 90-day follow-up visit showed no venous thromboembolism (VTE) recurrence and the major bleeding rate was 4%. Mortality rate at 30 and 90 days was 0%. CONCLUSIONS:Outpatient management for iPE in cancerpatients appears to be feasible and safe in selected cancerpatients.
Authors: Paul D Stein; Fadi Matta; Patrick G Hughes; Zak N Hourmouzis; Nina P Hourmouzis; Rachel M White; Martina M Ghiardi; Matthew A Schwartz; Hillary L Moore; Jennifer A Bach; Robert E Schweiss; Viviane M Kazan; Edward J Kakish; Daniel C Keyes; Mary J Hughes Journal: Am J Med Date: 2016-04-21 Impact factor: 4.965
Authors: Dominique Farge; Henri Bounameaux; Benjamin Brenner; Francis Cajfinger; Philippe Debourdeau; Alok A Khorana; Ingrid Pabinger; Susan Solymoss; James Douketis; Ajay Kakkar Journal: Lancet Oncol Date: 2016-10 Impact factor: 41.316
Authors: Stavros V Konstantinides; Adam Torbicki; Giancarlo Agnelli; Nicolas Danchin; David Fitzmaurice; Nazzareno Galiè; J Simon R Gibbs; Menno V Huisman; Marc Humbert; Nils Kucher; Irene Lang; Mareike Lankeit; John Lekakis; Christoph Maack; Eckhard Mayer; Nicolas Meneveau; Arnaud Perrier; Piotr Pruszczyk; Lars H Rasmussen; Thomas H Schindler; Pavel Svitil; Anton Vonk Noordegraaf; Jose Luis Zamorano; Maurizio Zompatori Journal: Eur Heart J Date: 2014-08-29 Impact factor: 29.983
Authors: Noémie Kraaijpoel; Suzanne M Bleker; Guy Meyer; Isabelle Mahé; Andrés Muñoz; Laurent Bertoletti; Annemarieke Bartels-Rutten; Jan Beyer-Westendorf; Ettore Porreca; Carine Boulon; Nick van Es; Diana I Iosub; Francis Couturaud; Mercedes Biosca; Teresa Lerede; Philippe Lacroix; Anthony Maraveyas; Anita Aggarwal; Philippe Girard; Harry R Büller; Marcello Di Nisio Journal: J Clin Oncol Date: 2019-05-22 Impact factor: 44.544
Authors: Gary H Lyman; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Ann Alexis Prestrud; Anna Falanga Journal: J Clin Oncol Date: 2013-05-13 Impact factor: 44.544